[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-446135-105":59,"doc-detail-446135-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","cdc7-is-a-targetable-regulator-of-advanced-prostate-cancer","CDC7 is a targetable regulator of advanced prostate cancer","","CDC7 is a kinase regulating DNA replication and is elevated during neuroendocrine transdifferentiation in lung and prostate cancer. Findings show CDC7 is highly expressed in treatment-resistant prostate cancer, especially in neuroendocrine phenotype (NEPC). CDC7 depletion suppresses prostate cancer cell growth, invasion, and in vivo tumor progression. Treatment with the selective CDC7 inhibitor TAK-931 reduces proliferation, migration, and invasion, induces replication stress, and promotes apoptosis, supporting CDC7 as a therapeutic target for advanced disease.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/cdc7-is-a-targetable-regulator-of-advanced-prostate-cancer/446135/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/cdc7-is-a-targetable-regulator-of-advanced-prostate-cancer/446135.png","ImageObject",300,407,{"name":92,"@type":93},"Taylor Morgan","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-29",true,{"@type":102,"interactionType":103,"userInteractionCount":24},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What role does CDC7 play in advanced prostate cancer?","Question",{"text":112,"@type":113},"CDC7 regulates DNA replication and is found elevated in neuroendocrine transdifferentiation. The study identifies CDC7 as a critical regulator of prostate tumorigenesis and tumor progression.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does reducing CDC7 affect prostate cancer cells and tumors?",{"text":117,"@type":113},"Downregulation of CDC7 significantly reduces prostate cancer cell growth and invasion in vitro, and silencing CDC7 suppresses prostate tumor growth in vivo.",{"name":119,"@type":110,"acceptedAnswer":120},"What is the impact of inhibiting CDC7 with TAK-931?",{"text":121,"@type":113},"TAK-931 treatment significantly reduces proliferation, migration, and invasion of aggressive prostate cancer cells. It also causes an abnormal cell cycle profile consistent with induced replication stress and promotes apoptosis.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},446135,1791086793,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":24,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":41,"preview_page_count":4},1099523885336,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nCDC7 is a targetable regulator of advanced prostate cancer  \nAlifiani B. Hartono1, HyeonJi Hwang1, Sidharth Paparaju1, Shiqin Liu1, James D. Brooks2,3, Eva Corey4 & Tanya Stoyanova1,5􀀍  \nProstate cancer is estimated to contribute to over 35,000 deaths of men residing in the United States, with the majority fatality due to metastatic disease. CDC7 is a kinase that regulates DNA replication and is found elevated during neuroendocrine transdifferentiation in lung and prostate cancer. In this study, we demonstrate that CDC7 is highly expressed in treatment-resistant prostate cancer, with even higher levels observed in treatment-resistant prostate cancer with neuroendocrine phenotype (NEPC). We further identify CDC7 as a critical regulator of prostate tumorigenesis. Downregulation of CDC7 significantly reduces prostate cancer cells growth and invasion in vitro and silencing CDC7 suppresses prostate tumor growth in vivo. Furthermore, we demonstrate that the inhibition of CDC7 using TAK-931, a selective CDC7 inhibitor, significantly reduces the proliferation, migration, and invasion of aggressive prostate cancer cells. TAK-931 treated prostate cancer cells exhibit an abnormal cell cycle profile, suggesting that CDC7 inhibition induces replication stress and promotes apoptosis. Collectively, our findings demonstrate that CDC7 is a regulator of tumor progression in prostate cancer and represents new therapeutic target in advanced prostate cancer.  \nProstate cancer is the second leading cause of cancer in men, with more than 300,000 estimated new cases and 35,000 deaths expected in 2025 in the United States1. While the 5-year survival rate for localized prostate cancer is relatively high at 97%, those who are diagnosed with metastatic disease are given less than 31% survival rate2. Androgen deprivation therapy (ADT) is the current standard of care for metastatic prostate cancer. Although nearly all prostate cancer initially responds to ADT, a subset of these cells adapts and become resistant, leading to the progression of castration resistance prostate cancer (CRPC), a lethal form of the disease. While the predominant histological variant of CRPC is adenocarcinoma (adeno-CRPC), about 20% of CRPCs acquire neuroendocrine phenotype, commonly referred to as neuroendocrine prostate cancer (NEPC)3–6. NEPC is highly aggressive and resistant to inhibition of the AR-pathway due to downregulation of AR-expression6. Despite current treatment options, metastatic Adeno-CRPC and NEPC are invariably lethal, highlighting the urgent need for identifying new druggable targets and effective treatment modalities.  \nChanges in pathways that maintain genomic integrity often occur as cancer progresses. Genes that regulate the cell cycle arrest, such as TP53 and RB1, are often altered7,8, and high levels of the DNA replication complex proteins, such as members of the minichromosome maintenance complex (MCM) DNA helicase, have been observed in advanced prostate cancer9. CDC7 is a conserved serine/threonine kinase that is activated by the regulatory subunits of DBF410. The CDC7 and DFB4 complex (DDK) promotes DNA replication origin firing by site-specific phosphorylation of the MCM2, MCM4, and MCM6 proteins,11–14 that induce conformational changes and enable recruitment of the heterotetrameric GINS complex and cell division cycle 45 (CDC45) . This protein complex forms the active helicase known as CDC45-MCM2-7-GINS complex (CMG)15–18. CDC7 is also a key factor in maintaining genomic stability in response to DNA damage and stalled replication forks19–22. Increased CDC7 expression has been observed in many advanced cancer and is associated with poor prognosis in ovarian and triple-negative breast cancer23. In prostate cancer model systems, CDC7 promotes the differentiation of adeno-CRPC into NEPC24. Newly available CDC7 inhibitors have shown efficacy in various types of cancer and coul","cbCaiaCdVOmpHGSY","https://ap.wps.com/l/cbCaiaCdVOmpHGSY","pdf",2869609,12,"English","# Results\n## CDC7 is highly expressed in advanced prostate cancer","[{\"question\":\"What role does CDC7 play in advanced prostate cancer?\",\"answer\":\"CDC7 regulates DNA replication and is found elevated in neuroendocrine transdifferentiation. The study identifies CDC7 as a critical regulator of prostate tumorigenesis and tumor progression.\"},{\"question\":\"How does reducing CDC7 affect prostate cancer cells and tumors?\",\"answer\":\"Downregulation of CDC7 significantly reduces prostate cancer cell growth and invasion in vitro, and silencing CDC7 suppresses prostate tumor growth in vivo.\"},{\"question\":\"What is the impact of inhibiting CDC7 with TAK-931?\",\"answer\":\"TAK-931 treatment significantly reduces proliferation, migration, and invasion of aggressive prostate cancer cells. It also causes an abnormal cell cycle profile consistent with induced replication stress and promotes apoptosis.\"}]","CDC7 is a targetable regulator of advanced prostate cancer | PDF",1790714257]